ArticleCancer communications (London, England)2024

Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.

Jiayu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.